Initial Analysis of ADNI Plasma Proteome Data Suggests Possible Protein Signatures for Alzheimer's

A plasma-based biomarker test for Alzheimer's could serve as a useful initial screen for the disease, as well as provide drugmakers with a way of selecting trial subjects that could be considerably less expensive than current methods like CSF analysis and PET scans.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.